1. Generics Bulletin
  2. >>Business
  3. >>Earnings

Krka: ‘Quantities, Capacities No Problem’ As Firm Looks To €2bn Milestone

EBITDA Margin Of 27% Will Face Continued Pressures Krka Admits; Guidance For 25%

 
• By Dean Rudge

Slovenian firm Krka addressed concerns about potential capacity restrictions during its recent preliminary annual earnings call, stating that it was continuing to work with partners while maintaining its own investments to meet its goals.

WoodenBlocks
• Source: Shutterstock

Krka has looked to brush aside any concerns that it will run into capacity constraint issues in the near term, as it continues to eye revenue growth of around 6% or more in 2025 to reach its group sales target of surpassing the €2bn ($2.08bn) mark for the first time in the company’s history.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

Samsung Bioepis Grows After US Launches

 
• By Dave Wallace

Samsung Bioepis has revealed first-quarter figures that reflect recent launches driving growth for the Korean biosimilars developer.

Despite Multiple Headwinds, Formycon Remains Positive For Its Biosimilars Growth

 
• By Urtė Fultinavičiūtė

Partnering opportunities, paused marketing, approvals, litigations, and many more. Formycon sets out the agenda for 2025, after seeing a bumpy start to the year.

Teva Crib Sheet Reveals Uzedy, Lenalidomide Expectations Ahead Of Q1

 
• By Dean Rudge

Teva is charting a new course under its ‘Pivot to Growth’ strategy, providing a memory aid for investors to better understand the firm’s financials going into 2025.

Alvotech Reveals Ramp-Up In Development As Sales Explode In 2024

 
• By Dave Wallace

With sales and profits shooting up in 2024, Alvotech has revealed plans to rapidly accelerate development to add between four and six programs to its pipeline of biosimilars every year, while at the same time unveiling details of several new brands that it will be seeking to challenge. The firm has also set out longer-term financial targets that anticipate more than trebling its revenues in the next three years.

More from Manufacturing

Biocon Biologics Teams Up With Civica On US Insulin Production

 
• By Dave Wallace

Biocon Biologics is partnering with Civica to supply insulin aspart drug substance that will be used for final US manufacturing by Civica at its plant in Petersburg, Virginia.

Viatris Rocked By Indore US Block, With $500m Revenue Sting Anticipated In 2025

 
• By Dean Rudge

Viatris anticipates that half-a-billion dollars will disappear from its top line in 2025 on the back of the recent import alert for its oral solids facility in Indore, with much of the pain being caused by the firm’s failure to have its generic version of Revlimid exempt from the restrictions.

Adcock Bemoans Wadeville Plant Jam As Trading Profit Dives, Revenues Freeze

 
• By Dean Rudge

South Africa’s Adcock Ingram struck a downbeat tone during its financial first-half results call, as multiple factors conspired to produce a performance “well below expectations.”